Published in J Clin Oncol on June 10, 2007
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol (2015) 2.29
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol (2009) 2.26
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc (2008) 2.01
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2009) 1.86
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol (2015) 1.55
Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer (2008) 1.53
What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology (2009) 1.49
[Not Available]. Can Urol Assoc J (2014) 1.38
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol (2010) 1.19
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol (2012) 1.04
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009) 1.03
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol (2011) 1.00
Energetics in colorectal and prostate cancer. J Clin Oncol (2010) 0.95
Cardiac and cognitive effects of androgen deprivation therapy: are they real? Curr Oncol (2010) 0.95
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep (2008) 0.94
Testosterone and cardiovascular disease in men. Asian J Androl (2012) 0.94
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int (2008) 0.92
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf (2011) 0.92
Chemotherapy and cardiotoxicity. Rev Cardiovasc Med (2008) 0.91
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw (2010) 0.90
Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis. J Neuroendocrinol (2009) 0.90
Prostate cancer: psychosocial implications and management. Future Oncol (2008) 0.90
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Parenteral oestrogen in the treatment of prostate cancer: a systematic review. Br J Cancer (2008) 0.86
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
All-cause mortality as an outcome in epidemiologic studies: proceed with caution. Eur J Epidemiol (2014) 0.85
Cardiovascular risk during hormonal treatment in patients with prostate cancer. Cancer Manag Res (2011) 0.85
Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs? Radiat Oncol (2008) 0.85
Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol (2008) 0.83
Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res (2008) 0.83
Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol (2013) 0.82
Concept and viability of androgen annihilation for advanced prostate cancer. Cancer (2014) 0.82
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer (2009) 0.82
Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. Asian J Androl (2015) 0.82
Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol (2007) 0.81
Androgen deprivation therapy toxicity and management for men receiving radiation therapy. Prostate Cancer (2012) 0.81
Management of advanced prostate cancer in senior adults: the new landscape. Oncologist (2012) 0.81
Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy (2016) 0.81
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol (2010) 0.80
Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age. J Radiat Res (2015) 0.79
Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J Androl (2012) 0.79
Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. Prostate Cancer (2011) 0.79
Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2013) 0.79
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies. Prostate Cancer (2016) 0.79
Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer (2012) 0.79
The side effects of hormonal therapy at the patients with prostate cancer. Contemp Oncol (Pozn) (2013) 0.79
Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol (2008) 0.78
Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience. Int J Clin Oncol (2011) 0.78
Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score. Prostate Int (2013) 0.78
Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis. Strahlenther Onkol (2009) 0.78
A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis (2016) 0.77
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2009) 0.77
Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65-69 Years. J Korean Med Sci (2016) 0.77
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs (2011) 0.77
Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer. Oncol Lett (2015) 0.77
Challenges of managing elderly men with prostate cancer. Nat Rev Clin Oncol (2014) 0.77
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Can Urol Assoc J (2009) 0.76
Testosterone replacement and prostate cancer. Indian J Urol (2012) 0.76
Neoadjuvant hormonal therapy preceding radical prostatectomy for clinically localized prostate cancer: early postoperative complications and biochemical recurrence. Korean J Urol (2011) 0.76
The impact of prostate cancer and hormonal therapy on bone. Rev Urol (2009) 0.76
High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl (2010) 0.76
The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol (2012) 0.75
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access J Urol (2011) 0.75
Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. Can Urol Assoc J (2017) 0.75
Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer? Nat Clin Pract Urol (2008) 0.75
Is androgen suppression therapy associated with early onset of fatal myocardial infarction? Nat Clin Pract Urol (2008) 0.75
Prostate cancer: cardiovascular mortality and androgen deprivation. Nat Rev Urol (2009) 0.75
Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers. Int J Circumpolar Health (2014) 0.75
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep (2016) 0.75
Radical radiotherapy for high-risk prostate cancer in older men. Oncologist (2012) 0.75
Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. BMC Cancer (2015) 0.75
Influence of age on androgen deprivation therapy-associated Alzheimer's disease. Sci Rep (2016) 0.75
Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer (2017) 0.75
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer (2017) 0.75
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World J Urol (2012) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol (2005) 5.40
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol (2012) 4.91
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Improving marginal likelihood estimation for Bayesian phylogenetic model selection. Syst Biol (2010) 4.32
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Prostate cancer screening--finding the middle road forward. N Z Med J (2005) 3.38
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol (2011) 3.21
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Intraoperative radiotherapy for breast cancer. Lancet Oncol (2004) 2.91
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol (2005) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Revised status of PSA testing in the early detection and treatment of prostate cancer. N Z Med J (2011) 2.54
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
Massive pulmonary embolism. Circulation (2006) 2.27
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med (2002) 2.25
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation (2004) 2.21
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol (2012) 2.19
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Int J Urol (2012) 2.10